Pediatrics

Numerous tools, technology platforms, and interventions have been developed to help teens with the difficult emotional and physical weight of managing the disease.

Although it is widely known that probiotics have anti-inflammatory effects and can alleviate clinical symptoms of atopic dermatitis (AD) in children, the effects of probiotics on AD in children have long been controversial.

The acceptance comes 5 days after the agency approved delandistrogene moxeparvovec-rokl to treat ambulatory pediatric DMD patients aged 4 to 5 years.

The accelerated approval of delandistrogene moxeparvovec-rokl is “based on expression of Elevidys micro-dystrophin observed in patients treated with ELEVIDYS,” according to Sarepta Therapeutics.

According to the FDA, the approvals “provide a new class of medicines taken by mouth to treat pediatric T2D.”

Odevixibat can now be used to treat cholestatic pruritus in young patients with Alagille syndrome (ALGS).

According to Dermavant, tapinarof cream 1% is a novel, aryl hydrocarbon receptor agonist in development as a once-daily topical cream.

The expanded labeling allows for an intravenously delivered formulation of ibuprofen (Caldolor) in infants aged 3 to 6 months.

Melody L. Berg, PharmD, MPH, BCPS, editorial director, American Society of Health-System Pharmacists, explains best practices, treatments, and preventive measures for sunburn, bug bites, and waterborne infections.

Part of the risk of developing kidney involvement begins when type 1 diabetes mellitus (T1DM) sets in and establishes itself in the patient, with up to 65% of children experiencing acute kidney injury during T1DM onset, which can further predispose to the development of future chronic kidney disease.

The REFLECT Scoliosis Correction System from Globus Medical is intended to correct progressive scoliosis in pediatric patients while simultaneously maintaining stability and motion as well as allowing for future modulated growth.

Though the Omicron variant caused the most symptoms in pediatric patients, there were no differences in adverse outcomes by COVID-19 variant.

IBS in pediatric patients has not been studied much, but new data reveals a possible treatment.

Post-COVID-19 conditions were more common in unvaccinated children than in children who had received at least 1 dose of a COVID-19 vaccine.

Data was presented at the 44th National Association of Pediatric Nurse Practitioners Conference regarding the effectiveness of vaccines and antivirals in preventing life threatening conditions.

At the 44th National Association of Pediatric Nurse Practitioners Conference, a session presented data explaining why teenagers with T1D are at high risk for developing anorexia and bulimia.

As more and more states legalize recreational marijuana, caregivers need to be vigilant about keeping products out of the reach of children.

The drug, called Leniolisib, is the first and only treatment approved in the United States for APDS, a rare primary immunodeficiency.

Pharmacogenetic testing and therapeutic drug monitoring are feasible in the inpatient psychiatric treatment setting.

All children included in the analysis with presymptomatic SMA achieved swallowing, oral nutrition, and airway protection outcomes.

Dupilumab met both its primary and key secondary endpoints in a phase 3 trial, demonstrating efficacy as a potential treatment for atopic hand and foot dermatitis.

Evkeeza, which treats a rare form of high cholesterol, is now approved for patients as young of 5 years.

Voxzogo is already available for patients over 5 years with a genetic cause of dwarfism. The PDUFA date is set for Oct. 21, 2023, and will potentially expand the drug to children 5 and under.

With nearly 250,000 kindergarten age children not receiving their recommended vaccines, pediatric health care providers search for solutions.

The vaccine was 73.2% effective in children aged 6 months to 4 years when administered during the Omicron-dominant phase.

The updated vaccine schedule includes vaccinations for influenza, pneumococcal disease, measles, mumps, and rubella (MMR) and COVID-19.

The FDA has granted Priority Review for linclotide (LINZESS; Ironwood Pharmaceuticals) for treating functional constipation in pediatric patients.

The FDA has updated its compounding guidelines for licensed pharmacies, hospitals, and health systems.

Results of a phase 3 clinical trial represent another avenue of treatment for children and adolescents living with type 2 diabetes.